Although to date there is no data on the benefit of such treatments before ART, a combined treatment with glucagon-like peptide-1 receptor agonist and metformin has been shown to have significant effects on weight loss and favorable results on endocrine and metabolic parameters, in women diagnosed with polycystic ovary syndrome and obesity or overweight [74]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.